GLI3 antibody

Catalog No. ABIN452568

This anti-GLI3 antibody is a Mouse Monoclonal antibody detecting GLI3 in EIA and IHC (fro). Suitable for Human.

Quick Overview for GLI3 antibody (ABIN452568)

Target: GLI3 (GLI Family Zinc Finger 3 (GLI3))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GLI3 antibody is un-conjugated

Application: Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: YPBH-2

Product Details anti-GLI3 Antibody

Cross-Reactivity (Details): Species reactivity (tested):Human.

Characteristics: Synonyms: Benign Prostatic Hyperplasia

Purification: Affinity Chromatography on Protein G.

Immunogen: Highly purified Benign Prostatic Hyperplasia (BPH).

Isotype: IgG

Application Details

Application Notes: This Benign Prostatic Hyperplasia antibody is suitable for use in ELISA andImmunohistochemistry. It was nor reaction in non-prostate normal tissue, neither prostate malignant tissuepositive. This anti-BPH antibody can react with some of well-moderately differentialprostate normal tissue and very rarely react with poor differential prostate normal tissue.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Reconstitution: Restore with Double distillated water to adjust the final concentration to 1.0 mg/mL.

Buffer: 0.01 M PBS, pH 7.2 without preservatives.

Preservative: Without preservative

Storage: -20 °C

Storage Comment: Store the antibody at -20 °C. After reconstitution, aliquot and store at -20 °C.
Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details for GLI3

Target: GLI3 (GLI Family Zinc Finger 3 (GLI3))

Alternative Name: BPH

Background: Benign prostatic hyperplasia (BPH) is a disease of unknown etiology that significantly affects the quality of life in aging men. Histologic BPH may present itself either as symptomatic or asymptomatic in nature. Benign prostatic hyperplasia (BPH), also known as benign enlargement of the prostate (BEP), is a condition that characterized by an increase in prostate size due to the formation of large nodules in the periurethral region of the prostate. Common in middle-aged and elderly men, benign prostatic hyperplasia leads to an obstruction of the urethra, thus interfering with normal urine flow and causing an urgency to urinate, as well as a decrease in urine flow. In some instances, benign prostatic hyperplasia can lead to recurrent urinary tract infections, bladder stones and kidney failure. These more serious afflictions are a direct result of an increase in the bacterial count within the bladder, a common phenomenon when urine flow is compromised. While mild cases of benign prostatic hyperplasia can be treated by a simple decrease in fluid intake, moderate to severe cases generally require medical treatment in the form of oral drugs or prostate surgery.Synonyms: Benign Prostatic Hyperplasia

Pathways: Hedgehog Signaling